linezolid

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Infections, Nosocomial

Conditions

Infections, Nosocomial

Trial Timeline

Jan 1, 2003 → Jan 1, 2006

NCT ID

NCT00150332

About linezolid

linezolid is a phase 3 stage product being developed by Pfizer for Infections, Nosocomial. The current trial status is completed. This product is registered under clinical trial identifier NCT00150332. Target conditions include Infections, Nosocomial.

What happened to similar drugs?

20 of 20 similar drugs in Infections, Nosocomial were approved

Approved (20) Terminated (3) Active (0)

✅amphotericin B liposomal (Ambisome)Astellas PharmaApproved

✅Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to EverolimusAstellas PharmaApproved

✅Ceftaroline fosamil + Ceftriaxone plus vancomycinAstraZenecaApproved

✅Kaletra + Isentress + Pre-study antiretroviral regimenMerckApproved

✅HPV9vMerckApproved

✅Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved

✅Daptomycin + VancomycinMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01805284	Approved	Completed	Feb 1, 2013	Sep 30, 2016	Pneumonia
NCT01040585	Pre-clinical	Withdrawn	Jul 1, 2010	Mar 1, 2011	Ventilator Acquired Pneumonia
NCT00255996	Phase 1	Completed	May 1, 2006	Jan 1, 2007	Burns
NCT01564758	Pre-clinical	Completed	Feb 1, 2004	Mar 1, 2005	Gram-Positive Bacterial Infections
NCT00147511	Approved	Completed	Jun 1, 2003	Jun 1, 2005	Gram-Positive Bacterial Infections
NCT00150332	Phase 3	Completed	Jan 1, 2003	Jan 1, 2006	Infections, Nosocomial

Competing Products

20 competing products in Infections, Nosocomial

See all competitors

Product	Company	Stage	Hype Score
DFA-02 Antibiotic Gel + DFA-02 Placebo Gel	Dr. Reddy's Laboratories	Phase 2	32
AAVLP-HPV + Placebo	2A Pharma	Phase 1	19
VN-0200 + Placebo	Daiichi Sankyo	Phase 1	29
VN-0200	Daiichi Sankyo	Phase 2	35
Micafungin	Astellas Pharma	Pre-clinical	26
amphotericin B liposomal (Ambisome)	Astellas Pharma	Approved	43
Parenteral micafungin application + Other parenteral antifungal drugs	Astellas Pharma	Pre-clinical	26
Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus	Astellas Pharma	Approved	43
Micafungin	Astellas Pharma	Pre-clinical	26
Micafungin	Astellas Pharma	Phase 1	29
Micafungin + Placebo	Astellas Pharma	Phase 3	32
Cefiderocol + Standard of Care	Shionogi	Phase 2	35
Dolutegravir + Rlipivirine + GSK1265744	Shionogi	Phase 1	29
Xeruborbactam Oral Prodrug + Ceftibuten	Shionogi	Phase 1	29
Cefiderocol + Standard of Care	Shionogi	Phase 2	35
Dolutegravir 50 mg twice daily + Dolutegravir placebo twice daily	Shionogi	Phase 3	40
Xeruborbactam Oral Prodrug + Ceftibuten + Xeruborbactam Oral Prodrug Placebo + Ceftibuten Placebo	Shionogi	Phase 1	29
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granules	Shionogi	Phase 1	29
GW810781	Shionogi	Phase 2	35
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusion	Shionogi	Phase 1	29